Compare Citius Pharmaceuticals Inc (CTXR) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Logitech International SA — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Logitech International SA trades at $103.69 (market cap $15.18B). The key difference: Logitech International SA is far larger — about 810.5× Citius Pharmaceuticals Inc's market cap, and Logitech International SA pays a 1.62% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | LOGI | |
|---|---|---|
Market Cap | $18.73M | $15.18B |
Sector | Health | Technology |
52-Week High | $1.82 | $126.69 |
52-Week Low | $0.48 | $85.84 |
Enterprise Value | $14.95M | $13.52B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Logitech (LOGI) trades at $106.33, up 3.26% today, with a bullish technical signal from moving averages and recent earnings beats. Revenue is projected to grow to $4.9B in 2026, with net income margin improving to 16.27%. The company faces near-term supply chain risks from a key semiconductor supplier shutdown, but strong demand in gaming and premium devices supports growth.
The outlook is mixed: solid fundamentals and analyst consensus target of $109.75 suggest upside, but supply constraints and mixed analyst ratings (26% Buy, 47% Hold, 26% Sell) indicate caution. Investors should weigh robust profitability against operational risks in the coming quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
